UCL Institute of Ophthalmology
- Current clinical trials of gene and cell therapy for sight loss
- Gene and cell therapies for inherited sight loss
- Gene and cell therapies for age-related macular degeneration (AMD)
- Gene therapy for diabetic eye disease
- Gene therapy for uveitis
- Gene therapy for corneal disease
Follow us (click an image below)
EyeTherapy Blog News
UCL researchers solve a major riddle of retinal degeneration research!
Mon, 26 Jan 2015 10:11:36 +0000
Today a paper published in Nature Communications from the Gene and Cell Therapy Group at the UCL Institute of Ophthalmology has shed light on why, until now, it has not been possible to effectively restore vision in rd1 mice – the world’s major model for retinitis pigmentosa (RP). The rd1 mouse is a model of […]Read more...
Professor Ali honoured for his contribution to research into retinal disease
Mon, 08 Sep 2014 12:27:36 +0000
Professor Robin Ali, PhD, Professor of Human Molecular Genetics and Head of the Department of Genetics, UCL Institute of Opthalmology has been awarded the Pioneer Award for his work in proof-of-concept studies that have demonstrated the feasibility of using gene therapy and cell transplantation to treat dysfunction and degeneration of the cells […]Read more...
Achromatopsia might not be as progressive as previously thought
Mon, 08 Sep 2014 11:17:16 +0000
A recent publication from the UCL Institute of Ophthalmology, Moorfields Eye Hospital, and the Medical College of Wisconsin indicates that for the majority of people with achromatopsia, the condition may not be as progressive as previously suggested. Data from this study by Aboshiha et al. demonstrated that for the majority of people with achromatopsia (a […]Read more...
Gene therapy for uveitis
Uveitis is a leading cause of sight loss amongst those of working age. Find out about how you can support our work and help develop effective therapies.
Uveitis is a group of conditions in which the immune system attacks the body's own cells, leading to damaging inflammation and loss of sight. The eye's local immune system is normally tightly regulated by a balance of cells and molecules that prevent large-scale inflammation; caused by many different triggers depending on whether the front of the back of the eye is affected, uveitis results from a failure of this tight regulation.
Uveitis is a common condition for which existing treatments have
limitations - they are short-acting and are often systemically delivered, and chronic use can have significant side-effects. We are therefore developing longer-acting, locally-administered treatments based on viral gene therapy.
We have shown that delivering genes that help control the immune system locally in the eye can prevent the most damaging types of inflammation seen in models of uveitis, and are improving the effectiveness of gene therapy for uveitis through ongoing studies.
- Collaborator: Andrew Dick
Page last modified on 03 dec 12 11:11